G.d. Searle & Company

Abbvie Inc.

G.d. Searle LLC

James C Stolzenbach

John Jeffrey Talley

Richard A Mueller

Daniel P Getman

Gary A DeCrescenzo

Michael L Vazquez

Rajeev D Gokhale

Aziz Karim

Martin John Griffin

James E Truelove

Dennis Andress

Ajit K Roy

Blas Coll Crespo

John J Brennan

James C Ottinger

Min S Chang

The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.

Methods for improving lipid profiles using atrasentan

Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alternatively, the formulation includes an aqueous solution of solubilizer.

Self-emulsifying drug delivery system

The present invention is directed to the preparation and use of retroviral protease inhibitors and combinations of retroviral protease inhibitors which are effective in preventing the replication of mammalian retroviruses, such as human immunodeficiency virus (HIV).

Retroviral protease inhibitors and combinations thereof

Growing community of inventors

Buffalo Grove, IL, United States of America

James C Stolzenbach